ACC 2.0 World Congress of Cardiology Virtual conference was held in Chicago, Illinois from March 28 to 30, 2020. Some breakthrough results were presented at the 69th annual scientific session including news and expert commentaries on the VICTORIA, Tailor PCI, COLCOT, Compass trial. Carbon Brand Solutions feels privileged to witness the revelation of the much-awaited results and findings of these breakthrough trials and was fortunate to gain insights from the leading experts in the field of cardiology.
Non-ST-elevation acute coronary syndrome (NSTE-ACS) assigns to a range of acute conditions resisting acute myocardial ischemia and infarctions that are common because of a sudden decrease in myocardial coronary blood flow.
Refractory hypertension (RfHTN) is a phenotype of antihypertensive therapy failure described as uncontrolled BP (≥130/80 mm Hg), regardless of adequate doses of 5 or more different classes of antihypertensive medications incorporating a long-acting thiazide-like diuretic (chlorthalidone) and a mineralocorticoid receptor antagonist (MRA).
Non-invasive imaging in the PESA (Progression of Early Subclinical Atherosclerosis) study revealed that 71% and 43% of middle-aged men and women, respectively, have evidence of subclinical atherosclerosis.
A coronary artery disease (CAD) responsiveness is focused on chromosome 15q26.1, recognized by genome-wide association studies.